Vermillion Shares Perk up on Appointment of Industry Veteran to Board | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Vermillion climbed as much as 23 percent on Nasdaq by early Friday afternoon, following the announcement that diagnostic industry veteran Bruce Huebner had been appointed to the molecular diagnostic company's board of directors.

In addition to being a director, Huebner is expected to lead a special committee to evaluate the current sales and marketing strategy of Vermillion's OVA1 test for ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.